arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AbbVie Inc.

ABBV
$245.14 ▲ +1.25 (+0.51%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Neutral
auto_awesome

Analytical Summary

AbbVie Inc. demonstrates solid fundamentals with strength in Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $433.7B
Dividend Yield 2.71%
Revenue Growth 8.6%
Op. Margin 24.6%
ROIC 15.8%
FCF / Share $10.07
Trailing P/E 103.4x
Price / Book
FCF Yield 4.1%
Debt / Equity -20.49
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$61.16B
↑ +8.6%
Net Income Profit after all expenses
$4.23B
↓ -1.2%
Operating Margin Operating profit as % of sales
24.6%
↑ +52.0% 81th
FCF / Share Free cash flow per share
$10.07
— -0.1%
Long-Term Debt Long-term obligations
$64.50B
↑ +8.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
76
Returns
6
Financial Health
87
Cash Quality
94

Dividend History

Dividend / share · sourced from SEC filings
$6.65 Latest / share
+5.7% YoY
+12.9% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters